男性乳腺癌的分子特征与死亡率:21基因复发评分分析
该研究比较了激素受体阳性乳腺癌男性和女性的21基因复发评分(RS)分布及基因表达差异,并分析RS与5年乳腺癌特异性生存(BCSS)的关系。结果显示男性RS≥31比例更高,且RS≥31的男性5年BCSS低于女性,提示RS检测对两性均有预后价值。
要点
- 男性乳腺癌患者RS≥31的比例高于女性(12.4% vs 7.4%)。
- 男性RS<11的比例也高于女性(33.8% vs 22.1%)。
- 男性RS≥31的5年BCSS为81.0%,低于女性的94.9%。
核心结论
- 男性乳腺癌具有独特的生物学特征,21基因RS检测对男性和女性均有重要预后作用。
研究设计与样本
- 研究纳入激素受体阳性乳腺癌患者,比较男性和女性的21基因RS结果及临床特征。
- 共纳入3806例男性和571115例女性。
- 生存数据来自SEER数据库,包括322例男性和55842例女性。
主要发现
- 男性平均年龄64.2岁,女性59.1岁(P < .001)。
- 男性RS≥31比例为12.4%,女性为7.4%(P < .001)。
- 男性RS<11比例为33.8%,女性为22.1%(P < .001)。
- 男性雌激素受体(ER)、增殖和侵袭基因组的平均基因表达高于女性。
- 男性RS<18的5年BCSS为99.0%(95% CI, 99.3% to 99.9%),RS 18-30为95.9%(95% CI, 87.6% to 98.7%)。
临床怎么用
- 对于男性激素受体阳性乳腺癌患者,可考虑进行21基因RS检测以评估预后。
- RS≥31的男性患者预后较差,可能需要更密切的随访或强化治疗策略。
局限性
- 生存数据仅来自SEER数据库的部分患者,样本量有限。
- 研究为回顾性分析,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Limited data exist on the molecular biology, treatment, and outcomes of breast cancer in men, and much of our understanding in this area remains largely an extrapolation from data in women with breast cancer. Materials and Methods We studied men and women with hormone receptor-positive breast cancer and the 21-gene Breast Recurrence Score (RS) results. Differences in clinical characteristics and gene expression were determined, and distribution of RS results was correlated with 5-year breast cancer-specific survival (BCSS) and overall survival. Results There were 3,806 men and 571,115 women. Men were older than women (mean age, 64.2 v 59.1 years; P < .001). RS < 18 predominated in both genders, but RS ≥ 31 was more frequent in men (12.4% v 7.4%; P < .001), as were very low scores (RS < 11; 33.8% v 22.1%; P < .001). Mean gene expression was higher in men for the estrogen receptor (ER), proliferation, and invasion groups. ER was lowest and progesterone receptor was highest in women younger than 50 years of age, with a progressive increase in ER with age. Men younger than 50 years of age had slightly lower ER and progesterone receptor compared with older men. Survival data were available from SEER for 322 men and 55,842 women. Five-year BCSS was 99.0% (95% CI, 99.3% to 99.9%) and 95.9% (95% CI, 87.6% to 98.7%) for men with RS < 18 and RS 18-30, respectively, and for women, it was 99.5% (95% CI, 99.4% to 99.6%) and 98.6% (95% CI, 98.4% to 98.8%), respectively. RS ≥ 31 was associated with an 81.0% 5-year BCSS in men (95% CI, 53.3% to 93.2%) and 94.9% 5-year BCSS (95% CI, 93.9% to 95.7%) in women. Five-year BCSS and overall survival were lower in men than in women. Conclusion This study reveals some distinctive biologic features of breast cancer in men and an important prognostic role for RS testing in both men and women.
引用
- Massarweh SA, Sledge GW, Miller DP, et al. Molecular Characterization and Mortality From Breast Cancer in Men. J Clin Oncol. 2018. PMID: 29584547. doi:10.1200/JCO.2017.76.8861
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。